Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment

Jingling Tang2, Na Xu1,2, Hongyu Ji1, Hongmei Liu1, Zhiyong Wang1, Linhua Wu1,2 1Department of Pharmacy, the Second Affiliated Hospital of Harbin Medical University, Key Laboratory of College in Heilongjiang Province; 2Department of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tang J, Xu N, Ji H, Liu H, Wang Z, Wu L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4f8e29591152443996e42a36a58090c7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f8e29591152443996e42a36a58090c7
record_format	dspace
spelling	oai:doaj.org-article:4f8e29591152443996e42a36a58090c72021-12-02T07:28:37ZEudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment1176-91141178-2013https://doaj.org/article/4f8e29591152443996e42a36a58090c72011-10-01T00:00:00Zhttp://www.dovepress.com/eudragit-nanoparticles-containing-genistein-formulation-development-an-a8506https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Jingling Tang2, Na Xu1,2, Hongyu Ji1, Hongmei Liu1, Zhiyong Wang1, Linhua Wu1,2 1Department of Pharmacy, the Second Affiliated Hospital of Harbin Medical University, Key Laboratory of College in Heilongjiang Province; 2Department of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, China Background: Genistein, one of the major isoflavones, has received great attention as a phytoestrogen and potential cancer chemoprevention agent. However, the dissolution and bioavailability of genistein from solid oral preparations is low due to its poor water solubility. Methods: In order to improve the oral bioavailability of genistein, genistein nanoparticles were prepared by the nanoprecipitation technique using Eudragit&reg; E100 as carriers and an optimized formulation of mass ratio (genistein:Eudragit E100, 1:10). The mean particle size of genistein nanoparticles was approximately 120 nm when diluted 100 times with distilled water. The drug-loaded nanoparticles were spherical on observation by transmission electric microscopy. Results: Encapsulation efficiency and drug loading of the genistein nanoparticles were approximately 50.61% and 5.02%, respectively. Release of drug from the genistein nanoparticles was two times greater than that from the conventional capsules. After administration of genistein suspension or genistein nanoparticles at a single dose of 100 mg/kg to fasted rats, the relative bioavailability of genistein from the nanoparticles compared with the reference suspension was 241.8%. Conclusion: These results suggested that a nanoparticle system is a potentially promising formulation for the efficient delivery of poorly water-soluble drugs by oral administration. Keywords: bioavailability, dissolution, genistein, nanoparticles, nanoprecipitation techniqueTang JXu NJi HLiu HWang ZWu LDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2011, Iss default, Pp 2429-2435 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Tang J Xu N Ji H Liu H Wang Z Wu L Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment
description	Jingling Tang2, Na Xu1,2, Hongyu Ji1, Hongmei Liu1, Zhiyong Wang1, Linhua Wu1,2 1Department of Pharmacy, the Second Affiliated Hospital of Harbin Medical University, Key Laboratory of College in Heilongjiang Province; 2Department of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, China Background: Genistein, one of the major isoflavones, has received great attention as a phytoestrogen and potential cancer chemoprevention agent. However, the dissolution and bioavailability of genistein from solid oral preparations is low due to its poor water solubility. Methods: In order to improve the oral bioavailability of genistein, genistein nanoparticles were prepared by the nanoprecipitation technique using Eudragit&reg; E100 as carriers and an optimized formulation of mass ratio (genistein:Eudragit E100, 1:10). The mean particle size of genistein nanoparticles was approximately 120 nm when diluted 100 times with distilled water. The drug-loaded nanoparticles were spherical on observation by transmission electric microscopy. Results: Encapsulation efficiency and drug loading of the genistein nanoparticles were approximately 50.61% and 5.02%, respectively. Release of drug from the genistein nanoparticles was two times greater than that from the conventional capsules. After administration of genistein suspension or genistein nanoparticles at a single dose of 100 mg/kg to fasted rats, the relative bioavailability of genistein from the nanoparticles compared with the reference suspension was 241.8%. Conclusion: These results suggested that a nanoparticle system is a potentially promising formulation for the efficient delivery of poorly water-soluble drugs by oral administration. Keywords: bioavailability, dissolution, genistein, nanoparticles, nanoprecipitation technique
format	article
author	Tang J Xu N Ji H Liu H Wang Z Wu L
author_facet	Tang J Xu N Ji H Liu H Wang Z Wu L
author_sort	Tang J
title	Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment
title_short	Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment
title_full	Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment
title_fullStr	Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment
title_full_unstemmed	Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment
title_sort	eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/4f8e29591152443996e42a36a58090c7
work_keys_str_mv	AT tangj eudragitnanoparticlescontaininggenisteinformulationdevelopmentandbioavailabilityassessment AT xun eudragitnanoparticlescontaininggenisteinformulationdevelopmentandbioavailabilityassessment AT jih eudragitnanoparticlescontaininggenisteinformulationdevelopmentandbioavailabilityassessment AT liuh eudragitnanoparticlescontaininggenisteinformulationdevelopmentandbioavailabilityassessment AT wangz eudragitnanoparticlescontaininggenisteinformulationdevelopmentandbioavailabilityassessment AT wul eudragitnanoparticlescontaininggenisteinformulationdevelopmentandbioavailabilityassessment
_version_	1718399399877410816

Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment

Ejemplares similares